EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab

Victoria Nikitina iD, Greta Santi Laurini iD, Nicola Montanaro iD, Domenico Motola iD

Headache: The Journal of Head and Face Pain · 2025-07 · 65 (7) · 1080-1094

DOI: 10.1111/head.14962 ↗

At a glance

Journal article in Headache: The Journal of Head and Face Pain, 2025-07. Written by Victoria Nikitina and 3 co-authors. Institution: Unit of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. Major MEDLINE topics: Migraine Disorders, Antibodies, Monoclonal, Humanized, Product Surveillance, Postmarketing, Antibodies, Monoclonal. Cited 5 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objectives/Background This study was undertaken to evaluate the postmarketing safety of monoclonal antibodies (mAbs) targeting the calcitonin gene‐related peptide pathway used for migraine prophylaxis through pharmacovigilance data analysis by examining suspected adverse events reported in Europe. Migraine is one of the most prevalent and debilitating neurological disorders globally. The introduction of mAbs targeting the calcitonin gene‐related peptide pathway has transformed migraine prophylaxis. However, their safety profiles in real‐world settings are not fully established, and ongoing safety monitoring is essential, as clinical trials may not capture all potential adverse drug reactions associated with new therapies.

Methods

A disproportionality analysis was carried out by analyzing postmarketing pharmacovigilance data from the EudraVigilance database, focusing on four mAbs: eptinezumab, fremanezumab, galcanezumab, and erenumab. Descriptive and statistical analyses were performed on data retrieved from the date of marketing authorization of each medicine up to June 16, 2024. The reporting odds ratio (ROR), information component, and empirical Bayes geometric mean were calculated to detect signals of disproportionate reporting comparing their safety profiles to topiramate, a standard preventive migraine treatment.

Results

A total of 14,285 reports had emerged; most of them were from females and concerned patients aged 18–64 years. The most frequently reported adverse drug reactions were primarily nonserious, aligning with literature and previously established safety profiles, such as fatigue and injection site reactions. The statistical analysis revealed 15 significant disproportionality signals: 11 for eptinezumab and four for galcanezumab. Eptinezumab highlighted potential new safety signals such as palpitations (ROR = 6.93, 95% confidence interval [CI] = 3.39–14.18), oropharyngeal pain (ROR = 7.19, 95% CI = 3.40–15.24), and erythema (ROR = 12.31, 95% CI = 4.58–33.12). These findings suggest a potential class effect, warranting further investigations and highlighting the importance of continued monitoring regarding the long‐term safety of mAbs.

Conclusion

Almost all of the most reported and statistically significant adverse events were nonserious and consistent with the existing literature. Given the chronic nature of migraine treatment, continuous pharmacovigilance monitoring is essential to ensure their constant safe use in clinical practice.

Subjects

MeSH terms (MEDLINE)

Migraine DisordersAntibodies, Monoclonal, HumanizedProduct Surveillance, PostmarketingAntibodies, MonoclonalPharmacovigilanceCalcitonin Gene-Related Peptide Receptor AntagonistsHumansFemaleMaleAdultMiddle AgedYoung AdultDatabases, FactualAdolescentEuropeAged

Author keywords

anti‐calcitonin gene‐related peptide monoclonal antibodiesmigrainepharmacovigilanceprophylaxis of migrainesafety

Substances

Antibodies, Monoclonal, HumanizedgalcanezumaberenumabAntibodies, MonoclonalfremanezumabeptinezumabCalcitonin Gene-Related Peptide Receptor Antagonists

Authors and institutions

  • Unit of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Alma Mater Studiorum University of Bologna, Bologna, Italy.

ORCID profiles: Victoria Nikitina, Greta Santi Laurini, Nicola Montanaro, Domenico Motola

Cite

APA

Nikitina, V., Santi Laurini, G., Montanaro, N., & Motola, D. (2025). Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14962

Vancouver

Nikitina V, Santi Laurini G, Montanaro N, Motola D. Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14962

BibTeX
@article{Nikitina2025,
  author = {Nikitina, Victoria and Santi Laurini, Greta and Montanaro, Nicola and Motola, Domenico},
  title = {Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  doi = {10.1111/head.14962}
}
Start for free →